3H-10000 / 3H Pharma - LARVOL DELTA

Preclinical development of 3H-10000, a novel vedotin antibody-drug conjugate for treatment of FGFR2b-expressing cancers (AACR 2026) - "Abstract is embargoed at this time."

ADC • Late-breaking abstract • Preclinical • Oncology

A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=170 | Recruiting | Sponsor: 3H Pharmaceuticals Co., Ltd.

First-in-human • New P1/2 trial • Gastric Cancer • Lung Cancer • Oncology • Solid Tumor